Weekly Research Analysts’ Ratings Updates for Zentalis Pharmaceuticals (ZNTL)

Several analysts have recently updated their ratings and price targets for Zentalis Pharmaceuticals (NASDAQ: ZNTL):

• 6/20/2024 – Zentalis Pharmaceuticals was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $5.00 price target on the stock, down previously from $28.00.
• 6/18/2024 – Zentalis Pharmaceuticals was downgraded by analysts at Wedbush from a “neutral” rating to an “underperform” rating. They now have a $4.00 price target on the stock, down previously from $15.00.
• 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $25.00. They now have an “outperform” rating on the stock.
• 6/18/2024 – Zentalis Pharmaceuticals had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $6.00 price target on the stock, down previously from $42.00.
• 6/18/2024 – Zentalis Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $8.00 price target on the stock, down previously from $38.00.
• 6/18/2024 – Zentalis Pharmaceuticals was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $9.00 price target on the stock, down previously from $29.00.
• 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $40.00 to $20.00. They now have a “buy” rating on the stock.
• 6/18/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $32.00 to $10.00. They now have a “buy” rating on the stock.
• 5/8/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $46.00 to $40.00. They now have a “buy” rating on the stock.
• 5/8/2024 – Zentalis Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $32.00. They now have a “buy” rating on the stock.

Zentalis Pharmaceuticals Trading Down 14.8 %

Shares of NASDAQ ZNTL traded down $0.62 during mid-day trading on Tuesday, reaching $3.57. The company had a trading volume of 1,296,949 shares, compared to its average volume of 1,069,719. The firm has a 50 day simple moving average of $9.95 and a two-hundred day simple moving average of $12.54. The stock has a market cap of $253.58 million, a P/E ratio of -1.07 and a beta of 1.71. Zentalis Pharmaceuticals, Inc. has a 52-week low of $3.43 and a 52-week high of $29.04.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million for the quarter, compared to analyst estimates of $35.00 million. During the same quarter in the prior year, the company earned ($1.07) EPS. On average, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.72 EPS for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now owns 633,680 shares in the company, valued at $7,591,486.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Diana Hausman sold 3,356 shares of the firm’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Quest Partners LLC acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC lifted its position in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 352.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after purchasing an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth $156,000.

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.